<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03458897</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00132776</org_study_id>
    <nct_id>NCT03458897</nct_id>
  </id_info>
  <brief_title>Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant</brief_title>
  <official_title>Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this research is to determine if it is feasible to perform serial
      magnetic resonance imaging (MRI) to evaluate the amount of bone marrow cells (also called
      cellularity) and iron stores before and after bone marrow transplantation for severe sickle
      cell disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>110 days post transplant</time_frame>
    <description>Feasibility will be measured by the number of subjects who undergo at least 2 of 4 scheduled functional MRI's</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI and hemoglobin S.</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Correlation between functional MRI result and hemoglobin S level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI and neutrophil engraftment</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Correlation between functional MRI result and time to neutrophil engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI and chimerism</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Correlation between functional MRI result and time to donor/ recipient chimerism</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>MRI arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with sickle cell disease undergoing bone marrow transplantation will undergo serial functional MRI (up to 4 scans).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serial functional magnetic resonance imaging (MRI)</intervention_name>
    <description>All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.</description>
    <arm_group_label>MRI arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 5 years.

          -  Diagnosis of SCD ([Hemoglobin SS (Hb-SS), Hemoglobin SC (Hb-SC) or Hemoglobin S-Beta
             thalassemia (Hb-Sβ) genotype].

          -  Patient is a candidate for an allogeneic HCT.

          -  Subject or guardians have given informed consent.

        Exclusion Criteria

          -  The need for general anesthesia for MRI.

          -  Subjects with implanted magnetic devices (e.g. pacemakers) that may malfunction or
             move in the strong magnetic field.

          -  A subject who is pregnant.

          -  Previous HCT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghada Abusin, MBBS MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Connie Varner</last_name>
    <phone>7347643140</phone>
    <email>convarne@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Varner</last_name>
      <email>convarne@med.umich.edu</email>
    </contact>
    <contact_backup>
      <phone>7347643140</phone>
    </contact_backup>
    <investigator>
      <last_name>Ghada Abusin, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Ghada Abusin</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>bone marrow cellularity</keyword>
  <keyword>bone marrow transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

